Human myeloid dendritic cells for cancer therapy: does maturation matter?
Jazyk angličtina Země Nizozemsko Médium print
Typ dokumentu časopisecké články, práce podpořená grantem, přehledy
PubMed
20665974
DOI
10.1016/j.vaccine.2010.05.042
PII: S0264-410X(10)00740-1
Knihovny.cz E-zdroje
- MeSH
- antigeny nádorové imunologie MeSH
- buněčné kultury MeSH
- cytokiny imunologie MeSH
- dendritické buňky imunologie fyziologie MeSH
- imunoterapie adoptivní metody MeSH
- lidé MeSH
- monocyty imunologie MeSH
- nádory terapie MeSH
- T-lymfocyty imunologie MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
- přehledy MeSH
- Názvy látek
- antigeny nádorové MeSH
- cytokiny MeSH
Dendritic cells form the connection between innate and adoptive mechanisms of the immune system. As antigen-presenting cells, dendritic cells are capable of presenting tumour antigen and effectively stimulating immune response targeted against a tumour. A number of preclinical and clinical studies document dendritic cells' potential in anti-cancer treatment. Increasing knowledge of dendritic cell biology is leading to improved methods for their preparation for clinical application. Unfortunately, there is to date no consensus specifying optimal conditions for dendritic cell preparation in vitro. This review summarizes the methods used for preparing myeloid dendritic cells derived from monocytic precursors while focusing on cytokine cocktails used for their growth, maturation, and functional adjustment.
Citace poskytuje Crossref.org
Complex evaluation of human monocyte-derived dendritic cells for cancer immunotherapy